PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
PRTC Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
PureTech Health plcNASDAQ: PRTC
Weighted Avg Shares · Q4 FY2025 · quarter ended Dec 2025
Weighted avg shares declines year over year
Q4 FY2025 weighted avg shares of 2.41M shares fell 91.0% year over year. Over 3 fiscal years it compounded at -55.8% a year.
Context
- Weighted avg shares increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 2.41M USD
- Year-over-year change
- -91.1%
- 4-year CAGR
- -46.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.41M | -91.1% |
| FY2024 | 2024-12-31 | 26.97M | -2.4% |
| FY2023 | 2023-12-31 | 27.63M | -1.2% |
| FY2022 | 2022-12-31 | 27.97M | -2.4% |
| FY2021 | 2021-12-31 | 28.66M | — |
Weighted Avg Shares vs competitors
How PRTC compares with its peers on the latest reported figures
- PRTC's FY2025 weighted avg shares of 2.41M shares is the lowest of the 11 companies compared; the peer median is 127.02M shares.
- Its year-over-year change of -91.1% is the lowest of 11, against a peer median of +23.8%.
- Over three fiscal years its annual growth of -55.8% compares with a peer median of +17.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 266.14M | +0.0% | +41.0% | |
| LTM Mar 2026 | 233.09M | +16.0% | +10.7% | |
| LTM Mar 2026 | 201.73M | +31.6% | +12.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | 166.7M | +4.0% | +2.4% |
| LTM Mar 2026 | 138.66M | +34.3% | +17.6% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 115.39M | +93.7% | +384.0% |
| LTM Mar 2026 | 111.46M | +12.7% | +17.7% | |
| LTM Mar 2026 | 98.27M | +94.3% | +117.4% | |
| LTM Mar 2026 | 43.27M | +112.6% | +166.1% | |
| LTM Mar 2026 | 20M | +14.7% | +18.2% | |
| FY2025 | 2.41M | -91.1% | -55.8% | |
| Peer median (excluding PRTC) | 127.02M | +23.8% | +17.9% | |
Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.98M | 2.09M | 3.33M | 4.83M | 4.66M |
| Cost of Revenue | 110.47M | 152.43M | 4.93M | 3.57M | 3.36M |
| Gross Profit | (100.49M) | (136.82M) | (1.6M) | 1.26M | 4.66M |
| Gross Margin | -1007.0% | -6546.2% | -48.1% | 26.0% | 100.0% |
| Research & Development | 81.52M | 116.11M | 96.24M | 54.28M | 45.74M |
| Selling, General & Admin | 30.76M | 35.67M | 48.36M | 27.49M | 20.65M |
| Operating Expenses | 160.26M | 60.99M | 54.55M | 140.41M | 103.18M |
| Depreciation & Amortization | 7.24M | 8.89M | 4.93M | 3.57M | 3.35M |
| EBITDA | 26.7M | (188.91M) | (11.63M) | 37.38M | (61.8M) |
| EBITDA Margin | 267.6% | -9038.9% | -349.2% | 774.3% | -1326.5% |
| Operating Income | (150.28M) | (197.81M) | (146.2M) | (136.1M) | (98.53M) |
| Operating Margin | -1506.0% | -9464.4% | -4390.4% | -2818.9% | -2114.7% |
| Interest Income | 214K | 5.8M | 16.01M | 22.67M | 13.05M |
| Interest Expense | 4.71M | 3.95M | 13.49M | 10.04M | 45.78M |
| Other Income / Expenses | 91.33M | 105.02M | 110.1M | 159.87M | (12.4M) |
| Income Before Tax | (58.95M) | (92.78M) | (36.1M) | 23.77M | (110.93M) |
| Pre-Tax Margin | -590.8% | -4439.4% | -1084.2% | 492.4% | -2380.9% |
| Income Tax Expense | 3.76M | (55.72M) | 30.53M | (4.01M) | (842K) |
| Net Income | (60.56M) | (50.36M) | (65.7M) | 53.51M | (109.74M) |
| Net Margin | -606.9% | -2409.3% | -1972.9% | 1108.3% | -2355.4% |
| EPS (Basic) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| EPS (Diluted) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| Weighted Avg Shares | 28.66M | 27.97M | 27.63M | 26.97M | 2.41M |
| Weighted Avg Shares (Diluted) | 28.66M | 28.48M | 27.63M | 26.97M | 2.41M |
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.